胡镜清
Hu Jingqing
人物简介
牵头全杜仲胶囊治肾虚型高血压随机对照试验与杜仲抗衰老研究
事迹
胡镜清现任中国中医药科技发展中心主任、研究员，曾任中国中医科学院中医基础理论研究所所长。他牵头承担国家重点研发计划相关课题，组织多家医疗机构完成全杜仲胶囊治疗轻度原发性高血压肾虚证的随机、双盲、安慰剂对照试验，证实其可显著降低诊室血压并提高血压达标率。
该成果2022年发表于《中国中西医结合杂志》，是杜仲类中成药循证研究的标志性临床试验之一。他还从古籍记载、传统用法与临床优势三个层面梳理杜仲学术脉络，并推进杜仲抗衰老方向的研究布局。
重要活动 / 事件
- 2022年组织多中心（中国中医科学院中医基础理论研究所、南京中医药大学第三临床医学院等）完成全杜仲胶囊降压RCT
- 2024年6月在吉安杜仲抗衰老学术交流会作《杜仲的传统用法与抗衰老研究》主题报告
代表贡献
- 作为通讯作者发表全杜仲胶囊降低轻度原发性高血压肾虚证患者血压的随机双盲安慰剂对照试验（《中国中西医结合杂志》2022年第42卷4期，60例、疗程12周）
- 该研究获国家重点研发计划项目（2019YFC1708500）资助，注册号ChiCTR1900021690
- 指导完成136例全杜仲胶囊调节高血压血压昼夜节律的临床研究
- 系统整理杜仲传统用法并主持杜仲抗衰老研究
Profile
Led a randomized controlled trial of Quan Duzhong Capsules for kidney-deficiency-type hypertension and research on Eucommia anti-aging
Story
Hu Jingqing is currently Director and Researcher of the China Center for Development of Traditional Chinese Medicine Science and Technology, and formerly Director of the Institute of Basic Theory of TCM, China Academy of Chinese Medical Sciences. He led relevant projects under the National Key R&D Program and organized multiple medical institutions to complete a randomized, double-blind, placebo-controlled trial of Quan Duzhong Capsules for mild essential hypertension of kidney-deficiency pattern, demonstrating that it significantly reduces office blood pressure and improves the blood pressure target attainment rate.
Published in the Chinese Journal of Integrated Traditional and Western Medicine in 2022, this result is one of the landmark clinical trials in evidence-based research on Eucommia-based Chinese patent medicines. He has also traced the academic lineage of Eucommia from three dimensions—ancient texts, traditional usage, and clinical advantages—and advanced the research agenda on Eucommia anti-aging.
Milestones
- In 2022, organized a multicenter RCT (involving the Institute of Basic Theory of TCM, China Academy of Chinese Medical Sciences; the Third Clinical Medical College of Nanjing University of Chinese Medicine; and others) of Quan Duzhong Capsules for blood pressure reduction
- Gave the keynote report 'Traditional Uses of Eucommia and Anti-Aging Research' at the Ji'an Eucommia Anti-Aging Academic Exchange Conference in June 2024
Key Contributions
- As corresponding author, published a randomized, double-blind, placebo-controlled trial of Quan Duzhong Capsules for reducing blood pressure in patients with mild essential hypertension of kidney-deficiency pattern (Chinese Journal of Integrated Traditional and Western Medicine, 2022, Vol. 42, No. 4; 60 cases; 12-week course)
- The study was funded by a National Key R&D Program project (2019YFC1708500); registration number ChiCTR1900021690
- Supervised a 136-case clinical study of Quan Duzhong Capsules in regulating the circadian rhythm of blood pressure in hypertension
- Systematically compiled the traditional uses of Eucommia and led research on Eucommia anti-aging
i 杜仲 · 杜仲全产业链大数据平台i DuZhong · Eucommia Full-Chain Data Platform
iduzhong.factorydossier.com